More results from Phase 1 study
Results of the evaluation of PSA values have been reported in the clinical phase 1 study that SpectraCure is currently running for treatment of patients with recurrent prostate cancer, using the company's photodynamic therapy (PDT) method. PSA (prostate-specific antigen) is a blood marker that can indicate the presence of a tumour in the prostate.The most recently treated patients had PSA values of 4.7 ng/ml and 5.7 ng/ml, respectively, prior to treatment. One month after treatment, the values had decreased to 0.3 ng/ml and 3.5 ng/ml, respectively.SpectraCure has previously reported